RT Journal Article
SR Electronic
T1 Combined <sup>18</sup>F-Fluoride and <sup>18</sup>F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 176
OP 183
DO 10.2967/jnumed.112.108803
VO 54
IS 2
A1 Iagaru, Andrei
A1 Mittra, Erik
A1 Mosci, Camila
A1 Dick, David W.
A1 Sathekge, Mike
A1 Prakash, Vineet
A1 Iyer, Victor
A1 Lapa, Paula
A1 Isidoro, Jorge
A1 de Lima, Joao M.
A1 Gambhir, Sanjiv Sam
YR 2013
UL http://jnm.snmjournals.org/content/54/2/176.abstract
AB 18F-FDG PET/CT is used in a variety of cancers, but because of variable rates of glucose metabolism, not all cancers are reliably identified. 18F− PET/CT allows for the acquisition of highly sensitive and specific images of the skeleton. We prospectively evaluated combined 18F−/18F-FDG as a single PET/CT examination for evaluation of cancer patients and compared it with separate 18F− PET/CT and 18F-FDG PET/CT scans. Methods: One hundred fifteen participants with cancer were prospectively enrolled in an international multicenter trial evaluating 18F− PET/CT, 18F-FDG PET/CT, and combined 18F−/18F-FDG PET/CT. The 3 PET/CT scans were performed sequentially within 4 wk of one another for each patient. Results: 18F−/18F-FDG PET/CT allowed for accurate interpretation of radiotracer uptake outside the skeleton, with findings similar to those of 18F-FDG PET/CT. In 19 participants, skeletal disease was more extensive on 18F− PET/CT and 18F−/18F-FDG PET/CT than on 18F-FDG PET/CT. In another 29 participants, 18F− PET/CT and 18F−/18F-FDG PET/CT showed osseous metastases where 18F-FDG PET/CT was negative. The extent of skeletal lesions was similar in 18 participants on all 3 scans. Conclusion: This trial demonstrated that combined 18F−/18F-FDG PET/CT shows promising results when compared with separate 18F− PET/CT and 18F-FDG PET/CT for evaluation of cancer patients. This result opens the possibility for improved patient care and reduction in health-care costs, as will be further evaluated in future trials.